Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Subscribe To Our Newsletter & Stay Updated